PROTECTING INTELLECTUAL PROPERTY.
PROTECTING EMERGING TECHNOLOGIES.
SERVICES
UTILITY, DESIGN & PLANT
PATENT PROSECUTION
PATENT LITIGATION
& ENFORCEMENT
PATENT PORTFOLIO
DEVELOPMENT & STRATEGY
FREEDOM-TO-OPERATE OPINIONS
TECHNOLOGY, COMPETITOR
& LANDSCAPE REVIEWS
IP AUDITS
& DUE DILIGENCE
INTELLECTUAL PROPERTY AGREEMENTS & LICENSING
TRADEMARK, COPYRIGHT
& OTHER IP SERVICES
DATA PRIVACY, TELEHEALTH & DIGITAL HEALTH ISSUES
REGULATORY APPROVAL & COMPLIANCE
VISION
Our vision is to provide unparalleled legal guidance to businesses by helping to generate value and growth through patents and intellectual property.
While a flower is budding, it is protected by a whorl of sepals that enclose the flower as it emerges and provide stability as it opens. This structure is the calyx. Like a calyx, we see our role as helping to ensure that seed stage and early stage companies have the protection and support they need to come into full bloom.
As practitioners, our goal is to be the foremost experts and most sought-out advocates on patent and IP issues central to emerging cutting-edge technologies. Founded in 2016, we were the first patent law boutique in California to focus on the cannabis industry, and we were among the first patent professionals anywhere to work on psychedelics.
PAIGE
Operations Advisor
A former research associate and project manager with several years of experience supporting a variety of clinical trials, a B.S. in Biochemistry and a minor in Psychology, and a profound interest in utilizing cannabis and psychedelics to treat mental health, Paige oversees work across all aspects and functions of Calyx Law as Operations Advisor.
GREG
Patent Agent
A registered patent agent with a degree in Chemistry, Greg brings his research experience in synthetic chemistry to his work at Calyx Law. Greg's patent practice has focused on drafting and prosecuting domestic and international patent applications, performing due diligence and freedom-to-operate analyses, and supporting litigation proceedings.
BEN
Patent Paralegal / Ops Lead
Pursuing a Master’s degree in Psychoactive Pharmaceutical Investigation at the University of Wisconsin-Madison School of Pharmacy, with a degree in History and Political Science, Ben is a Research Assistant at Calyx Law. Ben is experienced in archival research, and his interests include patent analysis and the sourcing of prior art.
PATRICK
Research Associate
A University of Minnesota Law School M.S. Patent Law graduate, UMN Technology Commercialization intern, and Johns Hopkins University M.S. Biotechnology student with the passion to explore the psychedelic patent space, Patrick brings his scientific and patent knowledge to Calyx Law to assist with prior art searches, due diligence, and patent drafting.
ANDREW
Research Associate
Andrew Ferns is a student at Western Oregon University obtaining his B.S. in Medicinal Chemistry & Pharmacology with plans to pursue a Master’s in Medicinal Chemistry. Andrew brings his unique background in psychedelic chemistry to his position as a Chemistry Research Associate to Calyx Law. Andrew is also an amateur mycologist and designs small-scale automated mushroom cultivation systems.
EMMA
Research Associate
A writer with expertise in scholarly research and education, especially relating to cannabis and psychedelic medicine, Emma is a Research Associate at Calyx Law. Emma has contributed work to leading platforms and publications in the cannabis and psychedelics spaces, and has written educational content for doctors and biotechnology companies.
GRAHAM
Founder / Patent Attorney
A registered patent attorney, with degrees in Biochemistry and Cognitive Neuroscience, Graham spent a decade representing Fortune 500 companies on their most critical patent matters, before founding Calyx Law to help cannabis and psychedelics ventures design and implement their patent and intellectual property strategies.
CHRIS
Patent Attorney
A registered patent attorney, with a degree in Physics and a Master’s degree in Religion, Ethics, & Politics, Chris has worked at the intersection of intellectual property, international trade, and public policy for Fortune 500 companies and non-profit organizations for over 15 years, focusing on patent litigation, licensing, and IP commoning.
MEDIA
UPCOMING:
Psychedelics are a step away from becoming prescription medicines. Companies are flooding in to capitalize on what could become a $100B market, backed by a massive onrush of investment, and accompanied by a deluge of patent filings. With innovation in mental healthcare stagnant for decades, and the need for new therapies more urgent than ever, surely turning psychedelics into patented pharmaceuticals will be a force for good? Or will it instead entrench existing inequalities, and lead to immense profit for a few, while stifling further innovation and leaving the neediest patients unable to access important and lifesaving treatments?
Will the mainstreaming of psychedelics simply repeat old mistakes, or will it be an opportunity to reimagine—and psychedelicize—the medicines system itself?
ALL MEDIA >
Psychedelic Alpha Trackers
